Widely available, well covered, and backed by Harrow

Get your patients started

ILEVRO® (nepafenac ophthalmic suspension) 0.3% is available on tiered and preferred coverage plans

COMMERCIAL INSURANCE

79 %*

of patients are covered^†

MEDICARE PART D

84 %*

of patients are covered^†

Largest branded ophthalmic NSAID clinical trial program^1-3^‡

Review efficacy

Stay connected with us

Get in touch

Data provided through MMIT and are current as of 7/24/2023. The information provided in this website is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation or warranty of any kind by any plan or insurer referenced herein.

Terms and conditions may apply. Copay program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program.

Since 2005.

References: 1. ILEVRO (nepafenac ophthalmic suspension) 0.3% [package insert]. Harrow IP, LLC; 2023. 2. BromSite (bromfenac ophthalmic solution) 0.075% [package insert]. Cranbury, NJ: Sun Pharma Global FZE; 2016. 3. Prolensa (bromfenac ophthalmic solution) 0.07% [package insert]. Bridgewater, NJ: Bausch & Lomb; 2016.

INDICATIONS AND USAGE

ILEVRO^® (nepafenac ophthalmic suspension) 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery.

IMPORTANT SAFETY INFORMATION

Contraindications

ILEVRO^® 0.3% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal anti-inflammatory drugs (NSAIDs).

Warnings and Precautions

Increased Bleeding Time – With some NSAIDs, including ILEVRO^® 0.3%, there exists the potential for increased bleeding time. Ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery.
Delayed Healing – Topical NSAIDs, including ILEVRO^® 0.3%, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
Corneal Effects – Use of topical NSAIDs may result in keratitis. In some patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including ILEVRO^® 0.3%, and should be closely monitored for corneal health.

Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events, which may become sight threatening. Topical NSAIDs should be used with caution in these patients.

Use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events.

Contact Lens Wear – ILEVRO^® 0.3% should not be administered while using contact lenses.

Adverse Reactions

The most frequently reported ocular adverse reactions following cataract surgery occurring in approximately 5% to 10% of patients were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation.

Dosage and Administration

One drop of ILEVRO^® 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery.

To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional information about ILEVRO^® 0.3%, please click here for the Full Prescribing Information.

References: 1. ILEVRO (nepafenac ophthalmic suspension) 0.3% [package insert]. Harrow IP, LLC; 2023. 2. BromSite (bromfenac ophthalmic solution) 0.075% [package insert]. Cranbury, NJ: Sun Pharma Global FZE; 2016. 3. Prolensa (bromfenac ophthalmic solution) 0.07% [package insert]. Bridgewater, NJ: Bausch & Lomb; 2016.